Crohn's Disease Treatment Shows Long-Term Success

Three-year study results suggest patients can maintain clinical remission with regular Tremfya maintenance dosing.

Updated on Oct. 23, 2026 in Cancer

Gouache-painted illustration of a single medical capsule on a sterile surface, representing long-term Crohn's disease treatment efficacy. — A three-year study reveals that regular Tremfya maintenance dosing effectively maintains clinical and endoscopic remission in adults living with Crohn's disease. AI Illustration. Upload story photo >

Live Poll

Does evidence of sustained drug performance through three years increase your trust in pharmaceutical treatments?

Long-term data show that Tremfya maintains high rates of clinical and endoscopic remission in patients with Crohn's disease over three years. The study also highlighted improved outcomes for those suffering from perianal fistulas.

Why it matters

These results provide clinicians and patients with important longitudinal data on the long-term effectiveness of interleukin-23 inhibitors for managing Crohn's disease. Understanding these outcomes helps in evaluating treatment plans for chronic intestinal inflammation.

Phase 3 trial findings demonstrate that 94% of patients on a 100mg dose achieved clinical remission at Week 144, while the FUZION study showed 28% fistula remission at Week 24 compared to 10% for placebo. Data indicate that 74% of participants remained on treatment throughout the three-year study.

The players

Johnson & Johnson

A pharmaceutical company that develops treatments for immunological diseases, including Crohn's disease.

The details

Tremfya works by inhibiting interleukin-23, a protein that plays a key role in the inflammatory response associated with Crohn's disease. The treatment protocol involves an initial intravenous induction phase followed by subcutaneous maintenance dosing. Endoscopic remission, which confirms the healing of intestinal tissue, was measured through direct examination of inflammation.

Week 24: Assessment of combined fistula remission in FUZION trial.
Week 144: Assessment of clinical remission in Phase 3 study.
October 2026: Findings presented at American College of Gastroenterology meeting.

Health Landscape

This research follows a significant trend in gastroenterology toward targeting specific cytokines to manage inflammatory bowel disease. It expands the available clinical data for advanced biologic therapies that aim to achieve deeper, endoscopic healing beyond symptom control.

Patients currently managing Crohn's disease may consider discussing these long-term results with their gastroenterologist to better understand treatment maintenance. It is important to review individual health history with a doctor before adjusting or starting any biologic therapy.

The takeaway

Achieving endoscopic remission is an important clinical goal for those with Crohn's disease, as it indicates physical healing of the intestinal lining. Patients should track symptoms consistently and consult their care team about how long-term maintenance data applies to their specific health plan.